Living Cell Technologies Limited has initiated a research collaboration with the Centre for Brain Research (CBR) at the University of Auckland. The research collaboration will explore how LCT’s products can reverse human brain neurodegenerative processes associated with pericytes (and other brain cells), which help sustain the blood-brain barrier and other homeostatic and haemostatic functions in the brain.
The agreement has two primary goals. The first is to extend the pipeline for LCT’s lead product NTCELL® by examining the effects of NTCELL on cell cultures derived from human brains with Alzheimer’s disease and Huntington’s disease. The second is to identify other encapsulated cell therapies which may have potential to treat these neurodegenerative disorders by examining whether they can promote neuroprotective effects in the brain.